ATM and Chk2 phosphorylation of histone 2AX and training H2AX foci correlates with PARP1 cells in S-phase of the expression. Tumors contain a h Higher proportion of replicating cells than normal tissue. Sensitizing effects of PARP inhibition of DNA replication ben CONFIRMS, and therefore affects the rapidly E7080 proliferating tumors than normal tissue. Thus, PARP inhibitors have the potential to increased therapeutic efficacy of chemotherapy and radiotherapy in a variety of tumor sites Hen by Erh Hen Sch Ending in a very replicating tumor cells while sparing normal tissues not bike there are often responsible for damage limitation dose interval Verl EXTENSIONS after radiotherapy. Therefore, the optimum dose and scheduling of simultaneous PARP inhibitor and a therapeutic agent for the treatment of cancer patients sorgf Validly con Us clinical studies.
Current technologies to evaluate tumor patients followed current technologies such as high-throughput DNA microarrays, quantitative real-time reverse transcriptase-PCR, protein chips by mass spectrometry, immunohistochemistry, IC-87114 immunofluorescence, are POWERFUL Hige tools for repair to develop DNA-Protein Expression Profiling patients to identify tumors that are sensitive to PARP inhibitors, and test the DNA repair biomarkers for cancer patients with the treatment reaction procedure ability to PARP inhibitors associated DNA, RNA and proteins. Many of these technologies by the availability of the entire human genome can be accelerated, however, developed due to the differences of tumor progression and the DNA content of a moving target for cancer treatment with a PARP inhibitor. There is to consider several aspects to be taken in the development strategy of biomarkers: 1 selection of biological samples are used: for example, are routinely owned clinical use of formalin-fixed paraffin-embedded tumor tissue samples is a valuable resource for discovery and validation of biomarkers large e k number of samples due to data on clinical outcomes can collected and analyzed quickly.
Circulating tumor cells of the patient’s blood are always discovered an essential tool in the diagnosis of malignancy and in monitoring the progression of cancer and the effect of treatment of cancer 2 Determination of biomarkers, DNA, RNA or protein k Everyone can as biomarkers, and the choice of biomarkers implications are used. 3 Determination of prognostic or pr Diktiven biomarkers. Pr Predictive biomarkers are initially Highest are to identify patients or not benefit from a specific treatment measure, w During a prognostic biomarker provides information on the prognosis of patients in the absence of treatment or the presence of a standard treatment. 4 Discovery, replication and validation of biomarkers. DNA microarray technology makes A broadband comprehensive analysis of the expression of gene transcription glicht simultaneously in a sample of cancer tissue and sensitive Ma the biomarker gene. The number of DNA variations such as mutation